Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.

@article{Gmezlechn2017UpgradingHC,
  title={Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.},
  author={M. Jos{\'e} G{\'o}mez-lech{\'o}n and Laia Tolosa and Mar{\'i}a Teresa Donato},
  journal={Expert opinion on drug metabolism & toxicology},
  year={2017},
  volume={13 2},
  pages={137-148}
}
INTRODUCTION Drug attrition rates due to hepatotoxicity are an important safety issue considered in drug development. The HepG2 hepatoma cell line is currently being used for drug-induced hepatotoxicity evaluations, but its expression of drug-metabolizing enzymes is poor compared with hepatocytes. Different approaches have been proposed to upgrade HepG2 cells for more reliable drug-induced liver injury predictions. Areas covered: We describe the advantages and limitations of HepG2 cells… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS